Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07322367 · ClinicalTrials.gov registry record · NA
A Mobile Patient Health Technology Intervention for Improving Lung Cancer Screening Rates in Eligible High Risk Patients
A NA study, sponsored by Wake Forest University Health Sciences.
- Recruiting
- Registry status
- NA
- Development phase
- 27,000
- Enrollment target
NCT07322367: Recruiting NA study, sponsored by Wake Forest University Health Sciences.
NCT07322367 is a NA study that is actively recruiting participants, run by Wake Forest University Health Sciences. The registered enrollment target is 27,000 participants, above the 1,403-participant average among 58,714 other NA trials with a reported enrollment target (1824% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07322367, a NA study, is actively recruiting participants, sponsored by Wake Forest University Health Sciences.
- RECRUITING
- Registry status
- NA
- Development phase
- 27,000 participants
- Enrollment target
Study Summary
To evaluate the real-world effectiveness and implementation strategies for mPATH-Lung, investigators propose a pragmatic, randomized controlled trial across an academic Learning Health System. The trial will contrast several approaches to participant outreach and will specifically target engaging fully powered cohorts of racial/ethnic minorities and rural residents.
Primary Outcome
Completion of the lung screening CT by participants.
Interventions
- OTHER Usual Care
- OTHER Portal Message with Reminder Text Messages
- OTHER Text Message with Reminder Text Messages
- OTHER Portal message only
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27,000 participants |
| Start Date | 2026-03-25 |
| Est. Completion | 2027-01 |
| Phase | NA |
What NCT07322367 shows while recruiting
NCT07322367 is an interventional study that assigns participants to a tested intervention. Its 27,000 participants enrollment target places it among the larger protocols in the corpus, above the 1,403-participant average among 58,714 other NA trials with a reported enrollment target (1824% higher).
The record links to 0 conditions, and to 4 interventions - of which Usual Care is the first listed.
NCT07322367 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07322367 about?
NCT07322367 is a clinical study titled "A Mobile Patient Health Technology Intervention for Improving Lung Cancer Screening Rates in Eligible High Risk Patients". To evaluate the real-world effectiveness and implementation strategies for mPATH-Lung, investigators propose a pragmatic, randomized controlled trial across an academic Learning Health System. The trial will contrast several approaches to participant outreach and will specifically target engaging fu...
What is the current status of trial NCT07322367?
This trial is currently recruiting. It is a NA study. The enrollment target is 27,000 participants. The study started on 2026-03-25. Estimated completion is 2027-01.
What interventions are being tested in trial NCT07322367?
The interventions under investigation include: Usual Care (OTHER), Portal Message with Reminder Text Messages (OTHER), Text Message with Reminder Text Messages (OTHER), Portal message only (OTHER).
Who is sponsoring clinical trial NCT07322367?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07322367's enrollment target sits among peer trials
27,000 9th of 2000 higher than 1,992 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04678193 · 27,000 participants
COVID-19 Risk Assessment for Hospitalization Outcomes and Epidemiology Efficacy
- NCT04494945 · 27,500 participants · NA
Identifying and Caring for Individuals With Inherited Cancer Syndrome
- NCT07300839 · 25,500 participants · Phase 3
A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age
- NCT03175302 · 25,240 participants
PREsurgical Cognitive Evaluation Via Digital clockfacEdrawing
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI